BERLIN--(BUSINESS WIRE)--Regulatory News:
NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that a leading international pharmaceutical company amongst the top-10 pharmaceutical companies by worldwide revenue1 has signed an agreement with NOXXON for the purpose of evaluating NOX-A12 in a new indication, which will remain undisclosed for competitive reasons.
“This agreement is an exceptional opportunity for NOXXON and a chance for NOX-A12 to deliver a broader therapeutic profile, while we continue to build value in our oncology pipeline in pancreatic, colorectal, and brain cancer and in our company,” said Aram Mangasarian, CEO of NOXXON.
NOXXON will supply NOX-A12 to the pharmaceutical company, which will fund and conduct preclinical studies to assess NOX-A12 in an indication which is a serious disease with significant unmet medical need. The market for this indication has been valued at more than a billion Euros. The studies are anticipated to run approximately 10 months, after which the parties may enter negotiations for rights to NOX-A12. As part of the agreement with the pharmaceutical partner performing the studies, NOXXON will not disclose the results until any negotiations are complete. As part of the agreement the pharmaceutical company has certain rights to participate in negotiations regarding the intellectual property relating to NOX-A12.
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 has delivered top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in December 2018 and further studies are being planned in these indications. The company initiated preparations for an additional trial with NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX‑E36 in patients with solid tumors both as a monotherapy and in combination. Further information can be found at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.